Bevacizumab and anlotinib combination therapy acts via HIF-1α suppression to exert synergistic anti-angiogenic and anti-tumor effects in non-small cell lung cancer.

ABSTRACT:

Introduction

Tumor angiogenesis is required for the progression of non-small cell lung cancer (NSCLC), and anti-vascular endothelial growth factor (anti-VEGF) antibody bevacizumab and multitarget tyrosine kinase inhibitor anlotinib are anti-cancer treatment options, the combined effect of which in NSCLC remains unclear.

Methods

A vascularized microfluidic chip was applied to model angiogenesis, together with in vitro assays, molecular analyses, and an in vivo mouse xenograft model, to evaluate therapeutic effects. Immunological changes were examined by assessing T-cell infiltration and cytokine levels, and the role of HIF-1α was validated using an inhibitor and an activator.

Results

Bevacizumab plus anlotinib (B+A) inhibited angiogenesis, reducing vessel

SUBMITTER: Simayi N 

PROVIDER: S-EPMC12484198 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature